Clinical trial
A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Furosemide in Healthy Male and Female Adults
NCT01438359 is registered in ClinicalTrials.gov with Vifor Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Furosemide in Healthy Male and Female Adults
- Lead sponsor
- Vifor Pharma
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2011
- Completion date
- September 30, 2011
- Enrollment
- 42 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy